The RCM consolidation wave shows no signs of slowing. In February 2026, Tenet regained full ownership of Conifer Health Solutions in a $2.7 billion transaction. Throughout 2025, GeBBS Healthcare sold to EQT for $850 million, Francisco Partners acquired AdvancedMD for $1.1 billion, and 47 PE deals involving RCM companies closed. Over the past four years, PE has invested $248 billion in the revenue cycle management sector across 2,357 deals. If you own an RCM company with $20 million or more in revenue, you have probably received multiple acquisition offers.
What most RCM entrepreneurs do not realize: The same recurring revenue characteristics that make PE firms willing to pay 12-30x EBITDA also make debt lenders willing to finance growth. You can participate in this consolidation wave as the acquirer, not the acquired.
Why It Matters
RCM companies with strong financial profiles can access debt financing to fund acquisitions while maintaining 100% ownership. The choice is not “accept the PE offer or stay stagnant.” Sophisticated RCM entrepreneurs are using debt to build larger platforms on their own terms, exiting later at higher multiples with more scale.
The Quick Take
What is happening:
- PE consolidation continues at record pace: February 2026 Tenet/Conifer $2.7B deal, multiple 2025 deals including GeBBS $850M and AdvancedMD $1.1B, plus 47 PE deals in 2025
- The math is compelling: Small RCM companies trade at 4-6x EBITDA, while platforms with $20M+ EBITDA command 15-20x multiples
- Debt markets are favorable: Declining interest rates and competitive lender environments make 2026 an opportune time for debt-financed growth
Why it matters to you:
- Your business model is highly bankable: B2B recurring revenue, 95%+ client retention rates, and predictable cash flows make RCM companies attractive to lenders
- Equity retention compounds value: Building a $60-70 million platform through debt-financed acquisitions can yield significantly higher exit proceeds than selling at $25-35 million today
- Control matters: Operating on your timeline, maintaining your culture, and executing your strategy without PE oversight has tangible value beyond financial returns
Why PE Wants Your RCM Company
The RCM market represents approximately $19 billion in annual healthcare IT spend and remains highly fragmented. Private equity firms see three compelling dynamics:
Recurring revenue model. RCM companies generate predictable B2B revenue with client retention rates typically exceeding 95%. This predictability makes future cash flows easier to forecast and debt easier to service.
Consolidation arbitrage. Acquiring multiple smaller RCM companies at 3-6x EBITDA and building a technology-enabled platform worth 12-30x EBITDA creates significant value. PE firms have executed this playbook successfully across dozens of healthcare business services verticals.
AI integration opportunities. Over 75% of U.S. health systems plan to expand AI-driven RCM automation by 2026. RCM platforms with credible AI strategies command premium valuations because they show margin expansion potential and competitive defensibility.
These factors explain why your inbox fills with acquisition inquiries. The consolidation wave is real, and it is accelerating.
What Makes RCM Companies Bankable
Debt lenders evaluate RCM companies differently than physician practices or hospital-dependent businesses. RCM’s B2B model eliminates several risks that concern healthcare lenders:
No reimbursement exposure. Unlike physician practices that depend on CMS rate decisions and commercial payor contract negotiations, RCM companies charge fees to healthcare providers. Your revenue does not fluctuate meaningfully when Medicare cuts reimbursement rates by 2.8%.
Predictable cash flows. Recurring monthly contracts produce cash flow visibility that traditional healthcare providers cannot match. Unlike SaaS companies with contractual payment obligations, RCM clients can terminate without penalty—but 95%+ retention rates allow lenders to support significantly higher leverage than conventional leveraged buyout structures.
Client diversification is achievable. Building a roster of 50+ provider clients is operationally feasible for RCM companies. Diversifying a physician practice to 50+ distinct payor contracts is not. This concentration risk distinction matters significantly to lenders.
Technology scalability. Software-enabled RCM companies can grow revenue without proportional increases in labor costs. Lenders understand margin expansion potential and view technology-enabled businesses as lower risk than labor-intensive services.
These characteristics place RCM companies in the most favorable tier of healthcare financing. Many owners assume “healthcare financing is difficult” without realizing they operate businesses lenders actively seek.
The Debt Financing Alternative
RCM company owners typically face a binary decision: accept the PE offer or decline and continue operating independently. Debt financing creates a third path.
The value creation comes from EBITDA multiple expansion, not just revenue growth. Market data shows clear valuation breaks by EBITDA scale: companies with sub-$3 million EBITDA trade at 4-6x multiples, while platforms reaching $5-10 million EBITDA command 10-12x, and those exceeding $20 million EBITDA can achieve 15-20x multiples from large PE firms seeking scaled platforms.
Example scenario: Your RCM company generates $7.5 million EBITDA. PE offers $60 million at 8x EBITDA. You receive $60 million but relinquish 100% of future upside.
The debt-financed rollup alternative:
Acquire 3-4 smaller RCM companies over 24 months. Target companies generating $2-4 million EBITDA trading at 5-6x multiples. Use debt financing of $15-25 million to fund acquisitions. Execute operational and technological synergies—consolidate platforms, eliminate redundant overhead, implement AI-driven automation. Build your EBITDA from $7.5 million to $22-25 million while maintaining 100% ownership.
The math comparison:
- Sell today: $7.5M EBITDA × 8x = $60M proceeds, 0% future equity
- Build then sell: Acquire $15M in additional EBITDA at 5-6x ($80-90M purchase price), grow combined EBITDA to $24M through synergies, exit at 16-18x = $384-432M enterprise value, minus $80-90M acquisition cost and debt = $280-340M proceeds
The multiple expansion from 8x to 16-18x creates the majority of value. Larger PE firms pay premium multiples for platforms with $20+ million EBITDA because these businesses offer institutional scale, diversified client bases, and technology infrastructure.
For entrepreneurs who built successful RCM companies from scratch, executing this playbook is operationally feasible—but requires the right capital structure and experienced lender partners. CAPX has guided RCM entrepreneurs through this exact strategy, structuring debt facilities that support acquisition growth while maintaining founder control.
When Debt Financing Makes Sense
This strategy works for RCM companies meeting specific criteria:
Strong financial profile. EBITDA exceeding $5 million, margins above 20%, and client retention rates above 90%. Lenders underwrite based on cash flow stability and growth trajectory.
Operational infrastructure. Technology platforms, documented processes, and management depth capable of integrating acquisitions. The owner cannot be the sole relationship manager for all clients.
Acquisition pipeline. Identified targets generating $2-5 million EBITDA. Fragmented markets favor acquirers who can move quickly when sellers emerge.
Owner readiness. Building through acquisitions requires 24-36 months of active involvement. Owners seeking immediate liquidity should sell. Owners willing to defer exit for potentially higher returns should consider debt.
Access to specialized lenders. For entrepreneurs who have never executed this playbook, creating the right capital structure and finding lenders with well-priced debt is critical. CAPX has structured and arranged multiple financings for RCM companies, connecting founders with lenders who understand healthcare business services and support multi-year growth strategies.
Why 2026 Is Favorable Timing
Three market conditions align in 2026:
Declining interest rates. SOFR has declined from its 5.4% peak, reducing the cost of debt financing. Lower debt service costs improve acquisition economics.
Competitive lender environment. Banks, private credit funds, and specialty healthcare lenders compete for quality RCM companies. Competition produces better terms for borrowers.
Valuation arbitrage persists. The spread between small company valuations (3-6x) and large platform valuations (12-30x) remains wide. This arbitrage creates opportunity for acquirers using debt to build scale.
Market timing does not guarantee success, but these conditions favor entrepreneurs considering debt-financed growth strategies.
The Bottom Line
If you receive PE acquisition offers, you operate a valuable business. The question is whether you want to sell that business today or use it as the foundation for building something larger.
RCM’s recurring B2B revenue model makes these businesses attractive to both PE buyers and debt lenders. Debt financing allows you to participate in the same consolidation dynamics driving PE interest while maintaining ownership and control.
This is not the right path for every RCM entrepreneur. But for owners with strong businesses, operational capabilities, and appetite for growth, 2026 presents a favorable environment to build rather than sell.
